Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783573 · ClinicalTrials.gov registry record · Phase 3
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,722
- Enrollment target
NCT02783573 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,722 participants.
The verdict
NCT02783573, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,722 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
Interventions
- DRUG Placebo
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,722 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02783573
The ClinicalTrials.gov registry entry for NCT02783573 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02783573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02783573 about?
NCT02783573 is a clinical study titled "A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia". The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
What is the current status of trial NCT02783573?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,722 participants. The study started on 2016-07-01. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT02783573?
The interventions under investigation include: Placebo (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02783573?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.